Project description
European consortium for coronavirus prevention, immunotherapy and drug discovery
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the most serious health threat of this century. The EU-funded CARE project is a coalition of 37 academic institutions, pharmaceutical companies and non-profit research organisations. The main consortium objectives are to develop therapeutics for the emergency response to the current SARS-CoV-2 pandemic by drug repositioning and to address future outbreaks through drug and virus-neutralising antibody discovery. The potency and safety of the therapeutic drug candidates will be assessed in vitro and in animal models. Moreover, virus-neutralising monoclonal antibodies will be generated and immune markers will be identified. The final lead candidates will be advanced into Phase 1 and Phase 2 clinical trials in humans.
Objective
The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in this century. According to the World Health Organisation Situation Report of March 28th 2020, 571,659 patients were diagnosed with Coronavirus Disease 2019 (COVID-19) and 26,493 deaths were reported globally. The wide spectrum of clinical symptoms, disease severity in high risk individuals, transmission efficiency and high mortality, raises an immediate need for vaccines or therapeutics. Given that the viral variant is new in the human population and emerged less than 4 months ago, there is no vaccine or approved therapies. The Corona Accelerated R&D in Europe (CARE) consortium is a coalition of 37 globally renowned academic institutions, pharmaceutical companies and non-profit research organizations who have committed to rapidly and efficiently address this emergent health threat, and the main objectives are: the development of therapeutics (i) to provide an emergency response towards the current COVID-19 pandemic by drug repositioning and (ii) to address the current and/or future coronavirus outbreaks by broad-spectrum small-molecule drug discovery and/or virus-neutralizing antibody discovery. To achieve this, a collection of repurposed drugs, focused libraries and small molecule libraries will be screened against SARS-CoV-2, other emerging SARS-CoV-2 clades and related coronavirus genera in phenotypic or target-based assays. A focused medicinal chemistry campaign will identify small-molecule hits, and Absorption, Distribution, Metabolism and Excretion (ADME), pharmacokinetic/pharmacodynamic (PK/PD), potency and safety of these therapeutic candidates will be assessed in vitro and in animal models. Virus-neutralizing monoclonal antibodies will be generated and further characterized. Immune markers will be identified contributing to the host immune responses to SARS-CoV-2 infections, and the correlation with clinical and virological outcomes will be determined. Finally, lead candidates will be advanced into Phase1 and Phase 2 clinical trials in humans. With this reactive response, the CARE consortium is dedicated to win the fight against coronavirus.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Keywords
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
75654 Paris
France
See on map
Participants (42)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
33000 Bordeaux
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
94010 Creteil
See on map
2340 Beerse
See on map
8152 Glattpark
See on map
75015 PARIS 15
See on map
1011 Lausanne
See on map
1003 Lausanne
See on map
DD1 3JT Dundee
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
60323 Frankfurt Am Main
See on map
38124 Braunschweig
See on map
31-007 Krakow
See on map
3000 Leuven
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
3001 Heverlee
See on map
2333 ZA Leiden
See on map
28046 MADRID
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
28046 Madrid
See on map
13353 Berlin
See on map
2860 SOBORG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
13284 Marseille
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75794 Paris
See on map
EH8 9YL Edinburgh
See on map
20148 Hamburg
See on map
23562 Lubeck
See on map
3584 CS Utrecht
See on map
3003 Bern
See on map
75015 PARIS
See on map
60064 North Chicago Il
See on map
2333 BE Leiden
See on map
51373 Leverkusen
See on map
55218 Ingelheim
See on map
DD1 4HN Dundee
See on map
69007 Lyon
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
98102 Seattle, Washington
See on map
100192 BEIJING
See on map
4056 Basel
See on map
CT13 9NJ Sandwich
See on map
64293 Darmstadt
See on map
30559 Hannover
See on map
34090 Montpellier
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
42117 Wuppertal
See on map
91190 GIF-SUR-YVETTE
See on map
75017 Paris
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.